TW200505454A - Heteroaryl-fused pyrimidinyl compounds as anticancer agents - Google Patents

Heteroaryl-fused pyrimidinyl compounds as anticancer agents

Info

Publication number
TW200505454A
TW200505454A TW093115312A TW93115312A TW200505454A TW 200505454 A TW200505454 A TW 200505454A TW 093115312 A TW093115312 A TW 093115312A TW 93115312 A TW93115312 A TW 93115312A TW 200505454 A TW200505454 A TW 200505454A
Authority
TW
Taiwan
Prior art keywords
heteroaryl
compounds
anticancer agents
fused pyrimidinyl
pyrimidinyl compounds
Prior art date
Application number
TW093115312A
Other languages
English (en)
Chinese (zh)
Inventor
Wei-Bo Wang
Liana M Lagniton
Ryan N Constantine
Matthew T Burger
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of TW200505454A publication Critical patent/TW200505454A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093115312A 2003-05-30 2004-05-28 Heteroaryl-fused pyrimidinyl compounds as anticancer agents TW200505454A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47468403P 2003-05-30 2003-05-30

Publications (1)

Publication Number Publication Date
TW200505454A true TW200505454A (en) 2005-02-16

Family

ID=33551504

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093115312A TW200505454A (en) 2003-05-30 2004-05-28 Heteroaryl-fused pyrimidinyl compounds as anticancer agents

Country Status (10)

Country Link
US (2) US7345046B2 (https=)
EP (1) EP1636238A1 (https=)
JP (1) JP2007500237A (https=)
KR (1) KR20060054187A (https=)
CN (1) CN100418971C (https=)
AU (1) AU2004247650A1 (https=)
CA (1) CA2526217A1 (https=)
MX (1) MXPA05012706A (https=)
TW (1) TW200505454A (https=)
WO (1) WO2004111058A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
ATE419249T1 (de) * 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
RU2007106552A (ru) * 2004-07-22 2008-08-27 Астразенека Аб (Se) Конденсированные пиримидоны, пригодные для лечения и предотвращения злокачественного новообразования
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
DE602005017283D1 (de) * 2004-08-18 2009-12-03 Astrazeneca Ab Ausgewählte kondensierte heterocyclen und deren anwendung
CN101027309B (zh) * 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
AU2006223461A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Fused thieno (2, 3-B) pyridine and thiazolo (5, 4-B) pyridine compounds for inhibiting ksp kinesin activity
CN101171052A (zh) * 2005-03-09 2008-04-30 先灵公司 抑制ksp驱动蛋白活性的化合物
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
AU2011205048B2 (en) * 2005-05-13 2013-05-02 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
CN101657203B (zh) * 2007-03-02 2012-09-05 卧龙岗大学 抗癌药的组合物及递送方法
WO2008147852A1 (en) * 2007-05-22 2008-12-04 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
TW200930375A (en) * 2007-12-21 2009-07-16 Exelixis Inc Benzofuropyrimidinones
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2015374367A1 (en) * 2014-12-29 2017-07-20 New Mexico Tech Research Foundation Synthetic rigidin analogues as anti-cancer agents, salts, solvates and prodrugs thereof, and method of producing same
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720969B2 (ja) * 1988-03-02 1995-03-08 吉富製薬株式会社 ３，４―ジヒドロチエノ〔２，３―ｄ〕ピリミジン化合物およびその医薬用途
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
MXPA03005152A (es) 2000-12-11 2004-10-14 Tularik Inc Antogonista de cxcr3.
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002364128B2 (en) 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
US7262187B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
JP2007500237A (ja) 2007-01-11
CA2526217A1 (en) 2004-12-23
CN1798749A (zh) 2006-07-05
EP1636238A1 (en) 2006-03-22
KR20060054187A (ko) 2006-05-22
MXPA05012706A (es) 2006-02-08
US20050065169A1 (en) 2005-03-24
US20080069817A1 (en) 2008-03-20
CN100418971C (zh) 2008-09-17
WO2004111058A1 (en) 2004-12-23
US7345046B2 (en) 2008-03-18
AU2004247650A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
IL175714A0 (en) Quinazolinone compounds as anticancer agents
TW200503719A (en) Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2004006859A3 (en) Platinum compound
TW200718689A (en) 2-Amino-quinazolin-5-ones
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
PL1697371T3 (pl) Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
IL153297A0 (en) Compounds and compositions for delivering active agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
MXPA05011785A (es) Moduladores positivos de receptores de acetilcolina nicotinicos.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
MY133682A (en) Substituted pyrroles
MX2010004313A (es) Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.